This study further revealed the heterogeneity of CRC through single-cell sequencing (sc-seq) and explore the interactions between the TME from a precision medicine perspective, identifying PRSS22 as new therapeutic targets, optimizing treatment strategies, and ultimately improving the prognosis of CRC patients. This evidence concerns the gene PRSS22 and colorectal carcinoma.